Canal-U

Accueil > Résultats de recherche

Résultats de recherche

Trier par :

Nombre de programmes trouvés : 5

Label UNT Conférences

le 17/03/2006 (29m33s)

10ème colloque de biologie prospective- the ApoB/ApoA-1 ratio a new predictor of myocardial infarction, stronger than lipids and other common risk factors

...Dans le cadre du 10ème colloque de biologie prospective, le Docteur Goran Walldius nous expose le thème suivant : the ApoB/ApoA-1 ratio a new predictor of myocardial infarction, stronger than lipids and other common risk factors....

Conférences

le 01/12/2012 (58m17s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Robert ROSENSON)

... (Taxilicumab)➢ New LDL-lowering compounds: PCSK9 inhibitors, apoB antisense, ISISSession program:Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials?Speaker: Eric STROES, Amsterdam, NEDDiscussant: Robert ROSENSON,...

Conférences

le 01/12/2012 (1h6m55s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: The value of omics and mendelian randomization studies (Daniel SWERDLOW)

... (Taxilicumab)➢ New LDL-lowering compounds: PCSK9 inhibitors, apoB antisense, ISISSession program:Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials?Speaker: Eric STROES, Amsterdam, NEDDiscussant: Robert ROSENSON,...

Conférences

le 01/12/2012 (14m26s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Eric STROES)

... (Taxilicumab)➢ New LDL-lowering compounds: PCSK9 inhibitors, apoB antisense, ISISSession program:Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials?Speaker: Eric STROES, Amsterdam, NEDDiscussant: Robert ROSENSON,...

Conférences

le 01/12/2012 (16m50s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: Monoclonal Antibody Inhibitor of PCSK9 (Wolfgang KOENIG)

... (Taxilicumab)➢ New LDL-lowering compounds: PCSK9 inhibitors, apoB antisense, ISISSession program:Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials?Speaker: Eric STROES, Amsterdam, NEDDiscussant: Robert ROSENSON,...

Mon Compte